NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis $1.95 -0.11 (-5.34%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.1550-Day Range$1.95▼$2.9352-Week Range$1.95▼$10.66Volume13,662 shsAverage Volume517,995 shsMarket Capitalization$2.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get GT Biopharma alerts: Email Address Ad Behind the Markets"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...Click here to discover how Wall Street insiders are quietly preparing for a market crash >>> About GT Biopharma Stock (NASDAQ:GTBP)GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Read More GTBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTBP Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comGT Biopharma, Inc. (NASDAQ:GTBP) Short Interest UpdateAugust 15, 2024 | markets.businessinsider.comGT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateSeptember 8, 2024 | Behind the Markets (Ad)"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...June 27, 2024 | globenewswire.comGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ LeukemiaMay 21, 2024 | marketwatch.comGT Biopharma Shares Rise 16% After Direct Offering PricesMay 21, 2024 | markets.businessinsider.comGT Biopharma Announces $3.2 Mln Direct Offering Of Shares; Stock UpMay 21, 2024 | globenewswire.comGT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 20, 2024 | investorplace.comWhy Is GT Biopharma (GTBP) Stock Up 143% Today?September 8, 2024 | Behind the Markets (Ad)"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...May 18, 2024 | nasdaq.comGT Biopharma, Inc. Common Stock (GTBP)May 16, 2024 | benzinga.comRaymond W. Urbanski's Net WorthMay 16, 2024 | investorplace.comGTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024May 15, 2024 | msn.comGT Biopharma reports Q1 resultsMay 15, 2024 | globenewswire.comGT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMarch 27, 2024 | benzinga.comRecap: GT Biopharma Q4 EarningsMarch 26, 2024 | globenewswire.comGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 25, 2024 | msn.comGT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00February 14, 2024 | finance.yahoo.comGTBP Feb 2024 2.500 callSee More Headlines Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/08/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CUSIPN/A CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees8Year Founded1965Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-171.45% Return on Assets-98.14% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.79Miscellaneous Outstanding Shares1,417,000Free Float1,275,000Market Cap$2.76 million OptionableNo Data Beta0.61 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Comp: $1.04MMr. Manu Ohri (Age 69)CFO & Secretary Comp: $647.07kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific AdvisorKey CompetitorsOncternal TherapeuticsNASDAQ:ONCTPharmaCyte BiotechNASDAQ:PMCBTenX Keane AcquisitionNASDAQ:TENKPurple BiotechNASDAQ:PPBTAddex TherapeuticsNASDAQ:ADXNView All CompetitorsInstitutional OwnershipDekaBank Deutsche GirozentraleSold 115,287 shares on 8/8/2024Ownership: 69.044%View All Institutional Transactions GTBP Stock Analysis - Frequently Asked Questions How have GTBP shares performed this year? GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP stock has decreased by 74.5% and is now trading at $1.95. View the best growth stocks for 2024 here. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($2.24) earnings per share for the quarter. When did GT Biopharma's stock split? GT Biopharma shares reverse split on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GT Biopharma's major shareholders? Top institutional shareholders of GT Biopharma include DekaBank Deutsche Girozentrale (69.04%). Insiders that own company stock include Michael Martin Breen and Manu Ohri. View institutional ownership trends. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTBP) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts